Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)

for the Expert Group on Inositols in Preclinical and Clinical Research

Research output: Contribution to journalReview articlepeer-review


It is well known that myo-inositol (MI) and D-chiro-inositol (DCI) are insulin-sensitizing agents, and MI is of proven utility in polycystic ovary syndrome (PCOS). In addition, MI plays a pivotal role in the physiology of reproduction, and has beneficial effects on the development of oocytes, spermatozoa, and embryos. By contrast, DCI has little effect on spermatozoa, but high concentrations in the ovary can negatively affect the quality of oocytes and the blastocyst. Overall, the evidence in the literature supports the beneficial effects of MI in both female and male reproduction, warranting clinical use of MI in assisted reproductive treatment (ART).

Original languageEnglish
Pages (from-to)570-579
Number of pages10
JournalTrends in Endocrinology and Metabolism
Issue number8
Publication statusPublished - Aug 2020


  • assisted reproductive treatment
  • D-chiro-inositol, polycystic ovary syndrome
  • in vitro fertilization
  • infertility
  • myo-inositol

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Breakthroughs in the Use of Inositols for Assisted Reproductive Treatment (ART)'. Together they form a unique fingerprint.

Cite this